Trial Profile
A Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkins Lymphoma After High-dose Chemotherapy With Autologous Stem Cell Transplant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 30 Jan 2014 According to ClinicalTrials.gov record study status changed from active, no longer recruiting to completed.
- 25 Mar 2013 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 30 Apr 2012 Results published in the Journal of Clinical Oncology.